Charles Explorer logo
🇬🇧

Long-term response to sequential treatment with tyrosine kinase inhibitors in a patient with EGFR+ adenocarcinoma

Publication at Third Faculty of Medicine |
2021

Abstract

Lung cancer is one of the tumours with very bad prognosis. Patients with EGFR positive lung cancer are treated with tyrosine kinase inhibitors with good treatment tolerance and statistically significant improved survival outcome.

Case report presents long survival of the 78 years old patient with EGFR positive non-small cell lung cancer on targeted therapy.